Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study

<p>(a) Kaplan-Meier survival curves for comparison of OS between TACE + sorafenib group and TACE group (P&lt;0.001). (b) Kaplan-Meier survival curves for comparison of OS between TACE + sorafenib group and TACE group after propensity score matching (P=0.001).</p>

BioMed Research International

fig2

Figure 2

Figure 2: Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study 

Figure 2 | Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study 